ProfileGDS5678 / 1423037_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 89% 90% 89% 90% 84% 87% 80% 83% 94% 95% 94% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7510388
GSM967853U87-EV human glioblastoma xenograft - Control 27.0587789
GSM967854U87-EV human glioblastoma xenograft - Control 37.1663190
GSM967855U87-EV human glioblastoma xenograft - Control 47.1477789
GSM967856U87-EV human glioblastoma xenograft - Control 57.3230790
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0333984
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4788587
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6925580
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1033883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.102494
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3584595
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.1761594
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.6238395
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2955795